FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2988289969> ?p ?o ?g. }

• W2988289969 endingPage "1245" @default.
• W2988289969 startingPage "1245" @default.
• W2988289969 abstract "Abstract Background: SCD is characterized by chronic vaso-occlusive crises and multiorgan failure resulting in poor quality of life and early mortality (Bhatia/Cairo et al, BMT 2014). There is presently no curative therapy for patients with high risk SCD other than HLA-identical sibling AlloSCT. (Freed/Cairo et al BMT 2012). However, less than 15% of eligible SCD patients have an unaffected MSD with a 10-15% increase of graft failure and TRM (Talano/Cairo et al, EJH, 2015). Similarly, most patients lack a matched related donor and UCB is an inferior source in SCD recipients (Radhakrishman/Cairo et al, BBMT 2013). Haploidentical familial donors with SCD trait offers an opportunity for a new donor source for children with high risk SCD. To overcome HLA barriers, Geyer/Cairo et al (BJH, 2012) demonstrated that T cell depletion using CD34 enriched HPC products with PB MNC addback transplanted in pediatric recipients utilizing MUD was associated with sustained engraftment, low risk of aGVHD but limited by delayed immune reconstitution. Efforts to use FHI donors and T replete AlloSCT in patients with SCD were associated with high rates of graft failure (Bolanes-Meade J et al Blood 2012; Ruggieri et al BBMT 2011). We previously reported FHI CD34 enriched/PB MNC addback AlloSCT is feasible and well tolerated in patients with high risk SCD (Abikoff/Cairo, ASBMT 2015). Objective: To characterize immunological reconstitution following FHI AlloSCT with CD34 enriched grafts with PB MNC addback in children and adolescents with high risk SCD. Methods: 15 patients were evaluatedpretransplant at D+30, 60, 100 and 180 following FHI AlloSCT. GCSF mobilized HPC were collected by apheresis (Spectra OPTIA, Terumo BCT) and products underwent CD34 enrichment using the CliniMACS cell separation system (materials generously supplied by Miltenyi Biotec, Cambridge , MA) with a PB MNC addback dose of 2x10*5 CD3/kg. Immune cell and subset reconstitution was assessed by flow cytometry. NK function was determined by cytotoxic activity against K562 tumor targets at 10:1 E:T ratio by europium release assay and intracellular LAMP-1 (CD107a) and granzyme B expression by flow cytometry. Whole blood, T cell and RBC chimerism (CD71) determined by flow cytometry and by STR. Results: Patients achieved neutrophil and platelet engraftment in a median time of 10 and 16 days, respectively. By D+30, median whole blood donor chimerism was ≥93% and ≥95% at most recent followup (D+30-730). Median donor chimerism in the erythroid lineage was 95% by D+60, with 7 of 13 patients ≥99% at D+30. This was maintained at most recent followup (D+30-730). Median T cell chimerism was 90% (D+60-550) and median NK cell chimerism was 90% by D+30 and maintained at ≥95% through D+730. NK (CD3-/56+) and NKT (CD3+/56+) cell reconstitution following FHI AlloSCT was rapid and peaked at D+30 (35.5±8.6%, 271x10*3/ul; 14.2±4%, 179x10*3/ul, respectively). Moreover, there was robust NK cell receptor expression reconstitution with high levels of activating receptors, NKp46, NKG2D and KIR2DS and inhibitory receptors NKG2A, CD94 and KIR2DL2/3 at D+30 [Fig 1]. NK cytotoxicity against K562 at E;T 10:1 peaked at D+30 (26±3%) and D+180 (28±3%) compared to pretransplant (16±2%, p<0.01). NK activation marker, CD107a, peaked at D+30 (37±9%) and D+180 (41±6%) and there was robust granzyme B degranulation at D+30. CD3+, CD4+, CD8+ and CD19+ immune reconstitution occurred between D+180 and D+270. One year absolute (mean±SEM) cells/ul of CD3+, CD4+, CD8+, CD19+ and CD56+ was 795±168, 408±102, 375±90, 815±352 and 204±37, respectively. [Fig 2] Conclusion: Immune reconstitution and donor chimerism was relatively rapid after FHI AlloSCT with CD34 enriched grafts with PB MNC addback in high risk SCD patients. The donor MNC addback after CD34 selection may in part contribute to rapid engraftment and immune reconstitution along with sustained donor chimerism. This research was supported by FDA grant 5R01FD004090. Disclosures Cairo: Celgene: Research Funding." @default.
• W2988289969 created "2019-11-22" @default.
• W2988289969 creator A5001697191 @default.
• W2988289969 creator A5006420164 @default.
• W2988289969 creator A5012947331 @default.
• W2988289969 creator A5017266140 @default.
• W2988289969 creator A5045255762 @default.
• W2988289969 creator A5050368246 @default.
• W2988289969 creator A5054509454 @default.
• W2988289969 creator A5065130464 @default.
• W2988289969 creator A5069361103 @default.
• W2988289969 creator A5069581168 @default.
• W2988289969 creator A5080362489 @default.
• W2988289969 creator A5087456665 @default.
• W2988289969 date "2016-12-02" @default.
• W2988289969 modified "2023-09-30" @default.
• W2988289969 title "Familial Haploidentical (FHI) Allogeneic Stem Cell Transplantation (AlloSCT) Utilizing CD34 Enrichment and PB MNC Addback in Children and Adolescents with High Risk Sickle Cell Disease (SCD): Rapid Engraftment, Immune Cell Reconstitution, and Sustained Donor Chimerism (IND 14359)" @default.
• W2988289969 doi "https://doi.org/10.1182/blood.v128.22.1245.1245" @default.
• W2988289969 hasPublicationYear "2016" @default.
• W2988289969 type Work @default.
• W2988289969 sameAs 2988289969 @default.
• W2988289969 citedByCount "2" @default.
• W2988289969 countsByYear W29882899692019 @default.
• W2988289969 countsByYear W29882899692022 @default.
• W2988289969 crossrefType "journal-article" @default.
• W2988289969 hasAuthorship W2988289969A5001697191 @default.
• W2988289969 hasAuthorship W2988289969A5006420164 @default.
• W2988289969 hasAuthorship W2988289969A5012947331 @default.
• W2988289969 hasAuthorship W2988289969A5017266140 @default.
• W2988289969 hasAuthorship W2988289969A5045255762 @default.
• W2988289969 hasAuthorship W2988289969A5050368246 @default.
• W2988289969 hasAuthorship W2988289969A5054509454 @default.
• W2988289969 hasAuthorship W2988289969A5065130464 @default.
• W2988289969 hasAuthorship W2988289969A5069361103 @default.
• W2988289969 hasAuthorship W2988289969A5069581168 @default.
• W2988289969 hasAuthorship W2988289969A5080362489 @default.
• W2988289969 hasAuthorship W2988289969A5087456665 @default.
• W2988289969 hasConcept C126322002 @default.
• W2988289969 hasConcept C203014093 @default.
• W2988289969 hasConcept C28328180 @default.
• W2988289969 hasConcept C2911091166 @default.
• W2988289969 hasConcept C54355233 @default.
• W2988289969 hasConcept C71924100 @default.
• W2988289969 hasConcept C86803240 @default.
• W2988289969 hasConcept C90924648 @default.
• W2988289969 hasConceptScore W2988289969C126322002 @default.
• W2988289969 hasConceptScore W2988289969C203014093 @default.
• W2988289969 hasConceptScore W2988289969C28328180 @default.
• W2988289969 hasConceptScore W2988289969C2911091166 @default.
• W2988289969 hasConceptScore W2988289969C54355233 @default.
• W2988289969 hasConceptScore W2988289969C71924100 @default.
• W2988289969 hasConceptScore W2988289969C86803240 @default.
• W2988289969 hasConceptScore W2988289969C90924648 @default.
• W2988289969 hasIssue "22" @default.
• W2988289969 hasLocation W29882899691 @default.
• W2988289969 hasOpenAccess W2988289969 @default.
• W2988289969 hasPrimaryLocation W29882899691 @default.
• W2988289969 hasRelatedWork W2005367603 @default.
• W2988289969 hasRelatedWork W2007186448 @default.
• W2988289969 hasRelatedWork W2054345956 @default.
• W2988289969 hasRelatedWork W2063931050 @default.
• W2988289969 hasRelatedWork W2089037140 @default.
• W2988289969 hasRelatedWork W2124601019 @default.
• W2988289969 hasRelatedWork W2297710864 @default.
• W2988289969 hasRelatedWork W2373952943 @default.
• W2988289969 hasRelatedWork W2534248358 @default.
• W2988289969 hasRelatedWork W2536282601 @default.
• W2988289969 hasRelatedWork W2558303258 @default.
• W2988289969 hasRelatedWork W2560481014 @default.
• W2988289969 hasRelatedWork W2573872323 @default.
• W2988289969 hasRelatedWork W2589014300 @default.
• W2988289969 hasRelatedWork W2912379363 @default.
• W2988289969 hasRelatedWork W2979798152 @default.
• W2988289969 hasRelatedWork W2980272254 @default.
• W2988289969 hasRelatedWork W2986815943 @default.
• W2988289969 hasRelatedWork W3001577794 @default.
• W2988289969 hasRelatedWork W3142489821 @default.
• W2988289969 hasVolume "128" @default.
• W2988289969 isParatext "false" @default.
• W2988289969 isRetracted "false" @default.
• W2988289969 magId "2988289969" @default.
• W2988289969 workType "article" @default.